TG Therapeutics Secures $750M Non-Dilutive Term Loan, Enhancing Financial Flexibility
TGTX sits 19% above its 52-week low of $25.28 on elevated volume (2.5× avg).
Summary
TG Therapeutics has secured a new $750 million non-dilutive term loan facility, which includes refinancing existing debt and establishing an uncommitted $250 million additional facility, enhancing the company's financial position.
Key Events · Financing and Capital Events · TGTX
-
Secured $750M Term Loan
TG Therapeutics amended its existing financing agreement to establish and fully draw a new $750 million term loan facility on March 18, 2026.
-
Non-Dilutive Capital
This debt financing provides substantial capital without issuing new shares, avoiding dilution for existing shareholders.
-
Refinancing and Flexibility
Proceeds were used to repay existing term loans, improving the company's debt structure, and an uncommitted $250 million facility offers additional financial flexibility.
-
Favorable Terms
The 2026 Term Loan matures in March 2031 and is secured by company assets, with interest rates tied to SOFR or base rate, reflecting the company's strong financial standing.
Analysis · TGTX · Life Sciences
This 8-K filing provides the definitive terms for a significant non-dilutive financing event, following a news announcement on March 19, 2026. TG Therapeutics entered into a first amendment to its existing financing agreement, establishing and fully drawing a new $750 million term loan facility. A portion of these proceeds was used to repay existing term loans, enhancing the company's balance sheet, and an uncommitted $250 million additional facility provides further financial flexibility. This substantial capital infusion strengthens TG Therapeutics' financial position and supports future growth initiatives without diluting existing shareholders, building on the strong 2025 financial results and raised 2026 guidance.
At the time of this filing, TGTX was trading at $30.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $25.28 to $46.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.